Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Prepaid Assets (2017 - 2026)

Crinetics Pharmaceuticals has reported Prepaid Assets over the past 9 years, most recently at $17.8 million for Q4 2025.

  • For Q4 2025, Prepaid Assets fell 24.56% year-over-year to $17.8 million; the TTM value through Dec 2025 reached $17.8 million, down 24.56%, while the annual FY2025 figure was $17.8 million, 24.56% down from the prior year.
  • Prepaid Assets for Q4 2025 was $17.8 million at Crinetics Pharmaceuticals, down from $46.9 million in the prior quarter.
  • Over five years, Prepaid Assets peaked at $46.9 million in Q3 2025 and troughed at $166000.0 in Q2 2021.
  • A 5-year average of $11.3 million and a median of $10.4 million in 2022 define the central range for Prepaid Assets.
  • Biggest five-year swings in Prepaid Assets: plummeted 95.84% in 2023 and later soared 5178.57% in 2024.
  • Year by year, Prepaid Assets stood at $11.0 million in 2021, then decreased by 2.31% to $10.8 million in 2022, then plummeted by 95.84% to $448000.0 in 2023, then soared by 5178.57% to $23.6 million in 2024, then dropped by 24.56% to $17.8 million in 2025.
  • Business Quant data shows Prepaid Assets for CRNX at $17.8 million in Q4 2025, $46.9 million in Q3 2025, and $20.4 million in Q2 2025.